摘要(英) |
In the highly competitive and increasingly globalized pharmaceutical industry, the development of data-based analytical methods and the application of data analysis techniques have become prioritized objectives for major pharmaceutical companies. Pharmaceutical R&D is a complex and time-consuming process traditionally focused on laboratory experiments.
However, in recent years, data-based approaches have gained significant attention and application in pharmaceutical R&D. These data-based methods include data analysis, machine
learning, and artificial intelligence, among other technologies, which can transform large amounts of data into valuable insights and provide essential data support for drug discovery, optimization, and evaluation.
This study uses a case company′s research product, a pharmaceutical drug for treating iron deposition, as an example to explore the application and value of data analysis methods based on data-driven approaches in the pharmaceutical research and development process. The study introduces the basic process of pharmaceutical R&D and discusses the differences in results generated by data analysis methods. It also introduces the design and application of Bootstrap, a commonly used statistical software in pharmaceutical companies. Furthermore, the
study conducts data processing, analysis, and result comparison using both traditional statistical methods and Bootstrap statistical software based on the research data provided by the case company.
In pharmaceutical research, conducting in vitro dissolution profile comparison tests primarily aims to predict the pharmacokinetics outcomes of drugs in vivo bioequivalence trials.
Based on research findings, the application of the statistical software Bootstrap has been shown
to address the issue of large coefficients of variation resulting from data processing using traditional statistical methods, especially in cases with small sample sizes, non-normal distribution, or the presence of extreme values. This statistical approach not only increases the reliability of the data but also effectively resolves the differences between sample data and population data. As a result, it has become an accepted statistical method by many pharmaceutical research companies and regulatory authorities. Utilizing appropriate data analysis methods can significantly enhance the drug development process, increase market competitiveness, and reduce the risk of failure |
參考文獻 |
一、 英文文獻
Banakar, U. V. (1991). Pharmaceutical dissolution testing. CRC Press.
Berry, I. R., & Martin, R. P. (2010). The Pharmaceutical Regulatory Process. CRC Press.
Borman, P., & Elder, D. (2017). Q2 (R1) validation of analytical procedures: text and methodology. ICH quality guidelines: an implementation guide, 127-166.
Clayden J., Greeves N., Warren S., & Wothers P. (2000). Organic Chemistry. Oxford University Press.
Davison, A. C., & Hinkley, D. V. (1997). Bootstrap methods and their application (No. 1). Cambridge university press.
De Muth, J. E. (2014). Basic statistics and pharmaceutical statistical applications. CRC Press.
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: new estimates of drug development costs. Journal of health economics, 22(2), 151-185.
Harrison, C. F. (2016). Pharmaceutical Regulatory Affairs: An Introduction for Life Scientists. Createspace Independent Publishing Platform.
Hickey, A. J., & Ganderton, D. (2016). Pharmaceutical process engineering. CRC Press.
Issar, M., Stark, J. G., & Shargel, L. (2007). Pharmacodynamic measurements for determination of bioequivalence. In Generic Drug Product Development (pp. 68-91). CRC Press.
Johnson, R. W. (2001). An introduction to the bootstrap. Teaching statistics, 23(2), 49-54.
Lampman, G. M., Pavia, D. L., Kriz, G. S., & Vyvyan, J. R. (2012). Spectroscopy (4th ed.).
Ludwig, A., Reimann, H., Bouwman‐Boer, Y., Fenton‐May, V., & Le Brun, P. P. H. (2015). Practical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products.
Marques, C. M., Moniz, S., de Sousa, J. P., Barbosa-Povoa, A. P., & Reklaitis, G. (2020). Decision-support challenges in the chemical-pharmaceutical industry: Findings and future research directions. Computers & Chemical Engineering, 134, 106672.
Nash, R. A., & Wachter, A. H. (2003). Pharmaceutical Process Validation: An International Third Edition. CRC Pr I Llc.
Norman, R. O., & Coxon, J. M. (1993). Principles of organic synthesis. CRC Press.
Nozari, H., & Szmelter, A. (2018). Global supply chains in the pharmaceutical industry. IGI Global.
Pacifici, E., & Bain, S. (2018). An Overview of FDA Regulated Products: From Drugs and Cosmetics to Food and Tobacco.
Sarker, S. D., Zahid Latif, & Gray, A. I. (2005). Natural Products Isolation. Springer Verlag.
Shargel, L., & Kanfer, I. (2013). Generic drug product development: solid oral dosage forms. CRC Press.
Skoog, D. A., Holler, F. J., & Crouch, S. R. (2017). Principles of instrumental analysis. Cengage learning.
Wang, D., & Bakhai, A. (2006). Clinical trials: a practical guide to design, analysis, and reporting. Remedica.
Watson, D. G. (2020). Pharmaceutical analysis E-book: a textbook for pharmacy students and pharmaceutical chemists. Elsevier Health Sciences.
二、 網站資料
個案公司甲生技醫藥股份有限公司官網。2023年5月6日取至: https://www.anxo.com.tw
Abbreviated new drug application (ANDA). (2022, December 16). U.S Food and Drug Administration. 2023年5月6日取至:
https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
Good ANDA submission practices guidance for industry. (2022, January 26). U.S Food and Drug Administration. 2023年5月6日取至:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-anda-submission-practices-guidance-industry
Update: Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies. (2014, October 02) . U.S Food and Drug Administration. 2023年5月6日取至:
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/update-bupropion-hydrochloride-extended-release-300-mg-bioequivalence-studies
ICH Topic Q1A (R2) Stability testing of new drug substances and drug products - scientific guideline. (2003, August). European medicines agency. 2023年5月6日取至:
https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline
ICH Q2 (R2) Validation of analytical procedures - scientific guideline. (1995, June). European medicines agency. 2023年5月6日取至:
https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline |